BioLife Solutions Inc. develops, manufactures and markets patented hypothermic storage, transport and cryopreservation (freezing) media for cells, tissues and organs. The company’s products are marketed to research facilities, hospitals and companies involved in cell therapy, tissue engineering, cord blood banking, toxicology testing and drug discovery.
The company today announced that it has become the leading supplier of pre-formulated GMP cryopreservation media for umbilical cord blood stem cells. This is a key segment of BioLife’s strategic biobanking market.
BioLife Solutions captured a significant share of this market through its expanding relationships with direct and indirect customers such as Community Blood Services and China Cord Blood Bank, through contract manufacturing customer OriGen Biomedical. Also aiding in this effort is its numerous contract banking services customers including ViaCord, Lifeforce Cryobanks and New England Cord Blood Bank.
Over the last two years, the company has built a market-leading position and a solid foundation of high-volume users of its GMP grade CryoStor and BloodStor stem cell freeze media products. BioLife management estimates that over 500,000 cord blood units were processed in 2010. It hopes to continue its growth with the introduction of a GMP syringe filling line with a plan to offer sterile, single-use syringe packaging options for these products later this year.
For further information on BioLife Solutions, please visit its website at www.biolifesolutions.com